The Covid-19 pandemic has created a big social emergency, and research progress is the only solution to face it and control it definitively. From the beginning of the crisis, IDIBELL has adapted to the new needs creating new lines of research to fight the virus and applying all the knowledge to the pandemic.
An IDIBELL-ICO study has identified that not only that antiangiogenic chemotherapy can induce more aggressiveness and malignancy in kidney tumors, but also, they have identified a biomarker to predict in which patients this may happen. These discoveries are another step towards making cancer therapy more personalized every day.
Drs. Jordi Carratalà, the coordinator of the Infectious Diseases and Transplants Program, and Fernando Fernández Aranda, principal investigator of the Psychiatry and Mental Health Group, both from IDIBELL and the Bellvitge University Hospital, have recently won the respective chairs of the Faculty of Medicine and Sciences of the Health of the University of Barcelona (UB).
The validation of this cellular mechanism will permit the identification of patients who have developed resistance to standard treatments and the implementation of more personalized medicine for prostate cancer.
